BioXcel Therapeutics
BTAI
BTAI
20 hedge funds and large institutions have $24.9M invested in BioXcel Therapeutics in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
20
Holders Change
+9
Holders Change %
+81.82%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
3
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.19M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$617K |
| 3 |
Renaissance Technologies
New York
|
+$443K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$302K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$250K |
Top Sellers
| 1 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
-$1.94M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$197K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$19K |
| 4 |
Morgan Stanley
New York
|
-$16.4K |
| 5 |
BlackRock
New York
|
-$9.84K |
